Advicenne S.A. (FRA:3MM)

Market Cap	18.36M -8.4%
Revenue (ttm)	5.90M -5.4%
Net Income	-6.21M
EPS	-0.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	145
Open	1.268
Previous Close	1.302
Day's Range	1.230 - 1.268
52-Week Range	1.084 - 2.200
Beta	n/a
RSI	35.68
Earnings Date	Mar 26, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3MM

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.